IDH2 and central nervous system cancer: Recently, the World Health Organization (WHO) added the presence of one of the recurrent point mutations in the isocitrate dehydrogenase genes (IDH1 or IDH2) and co-deletion of chromosomal arms 1p/19q to the glioma diagnosis criteria [3].